Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 15/20 | 0.63 |
| ▸ | AKT1 | P31749 | 5/20 | 0.56 |
| ▸ | AKT2 | P31751 | 1/20 | 0.52 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.52 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475956 | 0.89 | MC4R (0.62) | MC4RAKT1 | |
| SCHEMBL4682454 | 0.85 | MC4R (0.59) | MC4RAKT1AKT2AKT1S1AKT3 | |
| SCHEMBL4677948 | 0.82 | MC4R (0.56) | MC4RAKT1AKT2AKT1S1AKT3 | |
| SCHEMBL4515320 | 0.81 | MC4R (0.63) | MC4RAKT1AKT2AKT1S1AKT3 | |
| SCHEMBL4677487 | 0.81 | MC4R (0.55) | MC4RAKT1AKT2AKT1S1AKT3 | |
| Hydrochloric Acid SCHEMBL4516761 | 0.80 | AKT1 (0.58) | MC4RAKT1AKT2AKT1S1AKT3 | |
| SCHEMBL5472295 | 0.79 | MC4R (0.59) | MC4RAKT1AKT2AKT1S1AKT3 | |
| SCHEMBL4681135 | 0.79 | MC4R (0.59) | MC4RAKT1AKT2AKT1S1AKT3 | |
| SCHEMBL5339608 | 0.78 | AKT1 (0.56) | MC4RAKT1AKT2AKT1S1AKT3 | |
| SCHEMBL4684738 | 0.78 | MC4R (0.51) | MC4RAKT1AKT2AKT1S1AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885AKT1 2882/4885AKT2 1873/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885AKT1 2882/4885AKT2 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.